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Abstract: Prenatal exposure to tobacco smoke is a major risk factor for the newborn, increasing morbidity and even mortality in the neo-
natal period but also beyond. As nicotine addiction is the factor preventing many women from smoking cessation during pregnancy, nico-
tine replacement therapy (NRT) has been suggested as a better alternative for the fetus. However, the safety of NRT has not been well 
documented, and animal studies have in fact pointed to nicotine per se as being responsible for a multitude of these detrimental effects. 
Nicotine interacts with endogenous acetylcholine receptors in the brain and lung, and exposure during development interferes with nor-
mal neurotransmitter function, thus evoking neurodevelopmental abnormalities by disrupting the timing of neurotrophic actions. As ex-
posure to pure nicotine is quite uncommon in pregnant women, very little human data exist aside from the vast literature on prenatal ex-
posure to tobacco smoke. 
The current review discusses recent findings in humans on effects on the newborn of prenatal exposure to pure nicotine and non-smoke 
tobacco. It also reviews the neuropharmacological properties of nicotine during gestation and findings in animal experiments that offer 
explanations on a cellular level for the pathogenesis of such prenatal drug exposure.  
It is concluded that as findings indicate that functional nAChRs are present very early in neuronal development, and that activation at this 
stage leads to apoptosis and mitotic abnormalities, a total abstinence from all forms of nicotine should be advised to pregnant women for 
the entirety of gestation. 
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1. INTRODUCTION 
  Although knowledge about the negative effects on the fetus and 
the newborn of smoking during pregnancy is getting increasingly 
widespread, this habit still remains a great problem worldwide. The 
International Child Care Practices Study concluded in a survey of 
21 centers in 17 countries that an average of 22% of mothers and 
45% of fathers were smoking at the time of their child’s birth [94]. 
Although the geographical variations are large, this most likely 
represents the single largest modifiable neuropharmacological ex-
posure for the fetus. A large number of studies confirm that mater-
nal tobacco smoking during pregnancy adversely affects pre- and 
postnatal growth and increases the risk of fetal mortality [3,16,66], 
morbidity [45,131], cognitive development [7,33], and behavior of 
children and adolescents [133,134].  
  The possible adverse health effects of smokeless tobacco during 
pregnancy have received far less attention with a limited number of 
publications addressing this practice. Characterisation of this asso-
ciation is however important for several reasons. Firstly, millions of 
pregnant women use smokeless tobacco, predominantly in Africa 
and Asia [40] but also in Scandinavia [58]. These women are not 
exposed to the combustion products in tobacco smoke (e.g. carbon 
monoxide and cyanide) that may contribute to fetal hypoxia and 
reduced birthweight, but as nicotine levels may be very high the 
fetal exposure to nicotine may be unaltered or even increased. Sec-
ondly, as the hazards of smoking during pregnancy have become 
more evident in recent years, pregnant women are in rapidly in-
creasing numbers turning to other forms of nicotine. Therefore, the 
use of smokeless tobacco during pregnancy is an important clinical 
issue also for other countries than those primarily affected today. 
Finally, studying children exposed to smokeless tobacco, rather 
than tobacco smoke, facilitates comparison with the multitude of 
animal and cellular studies that have most often studied nicotine per
se.
  This article reviews current knowledge about the neuropharma-
cological effects of prenatal exposure to nicotine, a practise that 
compared to smoking is likely to be less harmful for the mother. 
Whether this is the case also for the fetus is however highly unclear. 
The article covers the current literature on studies in human infants 
exposed to nicotine primarily from other sources than tobacco 
smoke. Such data are quite scarce as use of smokeless tobacco   
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among pregnant women is relatively less common than smoking. 
Furthermore, it addresses data obtained in animal experiments that 
allow separation of several of the confounding factors that are diffi-
cult to control in the human situation. Although the relevance of 
results from another species are always difficult to determine, these 
findings are vital for our understanding of the effects of prenatal 
nicotine exposure. Finally, it examines possible neural mechanisms 
that may contribute to the adverse effects of prenatal exposure to 
nicotine. 
2. TOBACCO USE AMONG PREGNANT WOMEN 
a. Smoking During Pregnancy 
  It is estimated that 15 to 25% of women smoke during preg-
nancy [20,94,98] and although pregnancy motivates a minority of 
women to stop smoking for at least part of their pregnancy, most 
start again after delivery [98]. There is also a strong correlation 
between maternal smoking during pregnancy and young age, un-
married status and being from low socio-economic strata [68]. De-
spite current knowledge about the detrimental effects of smoking 
during pregnancy, the reduction in smoking among pregnant 
women is progressing very slowly. In some regions, e.g. Sweden, 
smoking has decreased at a higher rate and is now below 10% 
[125]. This decrease is however often coupled to a simultaneous 
increase in the use of smokeless tobacco, resulting in virtually unal-
tered levels of nicotine exposure for the fetus [125]. 
b. Other Sources of Nicotine 
  It is well established that nicotine replacement therapy (NRT) 
increases the likelihood of successful smoking cessation in non-
pregnant adults by 1.5 to 2-fold, regardless of what (if any) other 
efforts are made [112]. Whether this is also true for pregnant 
women is however unclear, and is discussed further below. Al-
though this is surely beneficial for the woman’s health, it is unclear 
if the offspring is any better off with this strategy. The main mode 
of action of NRT is thought to be the stimulation of nicotinic recep-
tors in the ventral tegmental area of the brain and the consequent 
release of dopamine in the nucleus accumbens. 
  In clinical praxis, pregnant women in most countries are ad-
vised to avoid any form of nicotine exposure if this is possible [95]. 
However, there is a general view that NRT during pregnancy is 
safer than smoking, recently reflected in a British Medical Journal 
editorial entitled “Nicotine replacement therapy in pregnancy is 
probably safer than smoking” [20]. NRT in pregnancy is therefore 
being encouraged in the absence of any direct evidence for its 
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ing during pregnancy without pharmacological support, but for 
those who do not succeed, or have previously failed in an attempt to 
quit, the use of NRT to support smoking cessation in pregnancy is 
often considered justifiable in relation to the risk of continued 
smoking [85]. Recent studies also confirm that nicotine replacement 
therapies are commonly prescribed or recommended to pregnant 
smokers by obstetric providers. Interestingly, pediatric clinicians 
were more reluctant to NRT prescription [97]. 
  As knowledge about the adverse effects of maternal smoking 
during pregnancy has increased over the last 15 years, women in 
several parts of the world have turned to alternative sources of nico-
tine. Similarly, smoking among women in South East Asia is rare, 
but use of smokeless tobacco is common [103]. Among women in 
India, smokeless tobacco has been demonstrated to constitute more 
than 95% of the total tobacco consumption, thereby by far surpass-
ing smoking as the primary source of nicotine during gestation [40]. 
In the Mumbai Cohort study [41], 58% of 59,527 lower-middle and 
lower-class women age 35 years and old reported current tobacco 
use, virtually all of which was smokeless. 
  A possible confounder of all studies of tobacco use during 
pregnancy, and in particular those emanating from developing 
countries, is that tobacco use tends to be associated with several 
other risk factors. In India, women using smoke-less tobacco had 
relatively lower socioeconomic status, weight, and educational 
status and were less likely to have had optimal antenatal care [44]. 
Similar associations are likely to occur in most countries and need 
to be considered when interpreting results. 
3. PHARMACOLOGICAL ACTIONS OF NICOTINE 
  The causative agent for the adverse effects of maternal smoking 
during gestation have been difficult to elucidate as cigarette smoke 
contains thousands of biologically active compounds, some of 
which are known to be fetal toxins (e.g. carbon monoxide (CO), 
metals and nicotine).  
  The adverse effects on the fetus of maternal smoking are likely 
to be multi-factorial, including indirect effects such as poor nutri-
tional status of the mother associated with the anorexigenic effect 
of nicotine, carbon monoxide exposure, and blood flow restriction 
to the placenta due to the vasoconstrictive effects of catecholamines 
released from the adrenals and nerve cells after nicotine activation. 
Direct effects on nicotinic acetylcholine receptors (nAChRs), which 
are present and functional very early in the fetal brain [5] are also 
likely to contribute.  
  Due to the pH of the cigarette smoke, only small amounts of 
nicotine are absorbed through the buccal mucosa [38]. In contrast, 
nicotine is rapidly absorbed when the tobacco smoke reaches the 
small airways and alveoli of the lung. This causes a quick rise in 
blood nicotine concentrations, but due to the eventual burnout of 
the cigarette, these levels also peak early and thereafter drop to 
lower levels [10]. Alternative sources of nicotine can be divided 
intotwodistinctgroups: a) pure nicotine products (nicotinic patches, 
gum, oral inhaler, nasal spray, lozenges or sublingual tablets), and 
b) smokeless tobacco (chewing tobacco, oral moist snuff and 
mishri). 
  Comparison of typical steady-state plasma nicotine concentra-
tions from different modes of administration has proven difficult. 
Whereas some studies report similar levels as cigarette smoking 
(typically ranging from 10-50 ng/ml) [96], others report substan-
tially higher [81] or lower [57] levels of nicotine. One reason for 
this discrepancy is different definitions of how to define “levels” of 
nicotine. Although the rise in the plasma and brain nicotine levels 
are slower using NRT than with smoking, concentrations of nico-
tine in the blood also decline much slower [12,57]. The total dose 
of nicotine (i.e. the area under the curve) is therefore in practise 
likely to be higher in persons using these formulations than after 
smoking a cigarette. The exception is nasal spray which provides a 
rapid delivery of nicotine almost similar to that seen after smoking 
[39,129]. Consequently, the risk of developing addiction has been 
demonstrated to be higher in subjects using nasal spray as com-
pared to other forms of NRT [135]. The overall risk was, however, 
much lower than for those using cigarettes.  
  An estimate of blood levels of nicotine with nicotine patches 
range from 10 to 20 ng/ml, and 5 to 15 ng/ml for nicotine gum, 
inhaler, sublingual tablet, and nasal spray [9,11,110](for review of 
kinetics see [57]). From these data it has been estimated that ad 
libitum use of smokeless tobacco results in one-third to two-thirds 
the concentration of nicotine that is achieved by cigarette smoking. 
Oral snuff contain concentrations of nicotine similar to cigarette 
tobacco, whereas chewing tobacco only contain about half of the 
concentration [132]. These formulations are also buffered to alka-
line pH to enable oral absorption and particularly moist snuff is 
capable of rapidly delivering high doses of nicotine [28]. Using 
nicotine patches, nicotine base is slowly absorbed through the skin, 
appearing in the bloodstream after about one hour. There is also a 
deposition in the skin, causing a continued absorption after removal 
of the patch corresponding to about 10% of the total dose [29]. 
  The plasma half-life of nicotine is about 2 h, provided a low 
level of first-pass metabolism. However, conflicting results exist 
and if urinary excretion of nicotine is used the terminal half-life 
averages 11 h [59]. This discrepancy may be partly explained by 
the fact that the latter method is considered more sensitive to lower 
levels of nicotine and that nicotine accumulates in body tissues. 
Therefore, although peak and trough levels follow each cigarette, 
basal nicotine levels rise during the day and the influence of peak 
levels may be of less importance [10]. This is of particular impor-
tance when discussing NRTs as these lack the typical peak and 
trough levels one would expect in cigarette smokers. After absorp-
tion, the distribution of nicotine in the body is rapid and has a par-
ticularly high affinity for the brain, heart and lungs. Nicotine’s pri-
mary metabolite is cotinine, but metabolisation also occurs by glu-
coronidation and N-oxi-dation [57]. Due to the relatively longer 
half-life of cotinine (17 h vs. 2 hours for nicotine in non-pregnant 
adults), this compound is often used as a marker of smoking as it is 
more stable and therefore easier to measure. 
  Nicotine exerts its effects by binding to nicotinic acetylcho-
linergic receptors (nAChRs), located in the brain, in autonomic 
ganglia, the adrenal medulla and the neuromuscular junctions. Sev-
eral subtypes of nicotinic cholinergic receptors exist, composed of 
different subunits, and activation of these receptors affects the re-
lease of a multitude of neurotransmitters including dopamine, nora-
drenaline, adrenaline, acetylcholine, serotonin (5-HT), -aminobu-
tyric acid (GABA), glutamate and neuromodulators such as sub-
stance P. Compared with the amount of data of the pharmacological 
dynamics of nicotine and cotinine in non-pregnant adults, less is 
known about the situation during pregnancy. There are, however, 
evidence that nicotine is metabolised more quickly in pregnancy. 
Plasma clearances of nicotine and cotinine are increased by 60% 
and 140%, respectively, and the half life of cotinine is reduced in 
pregnant women (9 h v 17 h in non-pregnant women) [22]. This 
indicates that the correlation between plasma levels of cotinine and 
intake of tobacco cannot be automatically transformed from the 
non-pregnant to the pregnant adult. 
  To date, however, the efficacy of NRT therapy in pregnancy is 
not known as evidence comes from only two studies and is incon-
clusive. A randomised study failed to demonstrate an increased 
likelihood of smoking cessation using nicotine patches, but the 
numbers studied were small, and the trial was underpowered to 
actually determine whether nicotine replacement was effective 
[138]. The second study was not placebo controlled and any effects 
by NRT were difficult to discriminate due to the experimental de-
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studies that have demonstrated positive effects of NRT in pregnant 
women. Also, these findings may reflect that pregnancy in itself is a 
very potent motivation for smoking cessation and as nicotine is 
metabolised more rapidly during pregnancy [22], higher doses than 
conventional NRT may be needed to obtain an effect. 
  When considering the potential fetal toxicity of any given drug, 
the disposition between the mother and the fetus is of vital impor-
tance. Nicotine easily crosses the placental barrier, and in humans it 
can be detected in the fetal circulation at levels exceeding maternal 
concentrations by 15%, while amniotic fluid concentrations of nico-
tine are 88% higher than maternal plasma [75,99]. This transfer is 
rapid with peak concentrations in the fetus after 15-30 minutes [75]. 
Nicotine also accumulates in breast milk, extending the nicotinic 
exposure to the postnatal period during breastfeeding [21,74]. Simi-
larly, an accumulation of nicotine in the fetal brain has been dem-
onstrated in rats [109]. 
4. EFFECTS OF NICOTINE IN HUMANS 
a. Effects on Pregnancy and the Newborn 
  The first suggestion of an association between maternal smok-
ing and preterm labour and delivery came in 1957 and identified a 
premature birth-rate (defined as birthweight <2500 g) nearly twice 
that of non-smokers. Also, a dose–response relationship of cigarette 
smoking and premature delivery was described [114]. This associa-
tion has thereafter been confirmed in a number of studies, but data 
have also given conflicting results. A recent study offers a possible 
explanation to the discrepancy as it indicates that maternal smoking 
in fact lowers the risk of very preterm birth due to gestational hy-
pertension, but increases the risk of very preterm birth due to other 
mechanisms [15]. This complexity may also explain why the effects 
of maternal smoking are connected to the parity of the mother. Also 
in a study from the United States, the association between smoking 
and preterm delivery before 33 weeks’ gestation was stronger than 
for later preterm delivery [111].  
  Women using smokeless tobacco have also been shown to give 
birth earlier than women not using tobacco (mean difference 6.2 
days), increasing the risk of preterm birth by a factor of 1.4. The 
crude relative risk for birth before 32 weeks was 3.7 and for birth 
before 28 weeks it was 7.2 [42]. Similar findings were seen in a 
study from South Africa, where snuff users had a significantly 
shorter gestational age than the both smokers and control subjects 
[128]. However, interpretation of this study is limited as data are 
limited and the demographical base is extremely complicated with a 
very high risk for confounding factors. 
  A number of studies have investigated the cardiovascular ef-
fects of nicotine during pregnancy, these have been reviewed exten-
sively elsewhere [23]. The conclusion of these studies is that NRT 
appears to have cardiovascular effects on both the mother and the 
fetus, but that the effects are rather small. Most of the studies deal 
with the effects of acute nicotine exposure, and will therefore not be 
further discussed in this article. It is, however, important to notice 
these findings as they point to other factors than uteroplacental 
insufficiency as being responsible for the detrimental outcome of 
nicotine during pregnancy. The hypothesis that other constituents of 
tobacco smoke than nicotine affect the cardiovascular system is 
corroborated also by recent findings from a study of all live births 
in Sweden 1999-2000. Whereas pre-eclampsia was reduced in 
smokers (adjusted odds ratio, 0.63) it was increased in snuff users 
(adjusted odds ratio, 1.58) [25]. This indicates that the protective 
factor against pre-eclampsia in cigarette smoke is a product of 
combustion rather than nicotine. In the absence of this protective 
factor, nicotine may in fact raise the pre-eclampsia risk through 
effects on the cardiovascular system, such as by causing endothelial 
dysfunction or raising blood pressure. Although it cannot be ruled 
out that additives in snuff (e.g. sodium and liquorice) cause an ele-
vation in blood pressure, this is unlikely as most brands of Swedish 
snuff do not contain liquorice and salt restriction has not been found 
to prevent pre-eclampsia [78]. 
  An association between maternal smoking and a reduced birth 
weight is also well established, displaying a clear dose-response 
pattern. In fact, between the years 1957 and 1986, over 100 studies 
(comprising more than 500 000 births) were published demonstrat-
ing that children born to smoking mothers have lower birthweights 
[76]. A review of pooled data concluded that the decrease in mean 
birthweight in infants of smoking mothers was 187 g (range 70–242 
g) [1]. The effect is however only seen if smoking is continued past 
gestational week 30, coinciding with the maximum growth of the 
fetus [49]. 
  Several studies from India have demonstrated a relationship 
between smokeless tobacco use during pregnancy, mainly mishri (a 
pyrolysed and powdered tobacco), and effects on birthweight. Of 
1388 singleton births in a Pune hospital, tobacco chewers had ba-
bies with a consistent birth weight deficit of 100-200 g, independent 
of maternal weight, socioeconomic status, and gestational age [67]. 
In another Indian study from the city of Mumbai of 178 deliveries, 
the proportion of low birth weight babies in users was twice as high 
as that of non-users [82]. A prospective, population based study 
from the same region corroborated these findings with babies born 
to mothers using smokeless tobacco being on average 105 g lighter 
[42]. When adjusted for gestational age, the difference was 87 g 
with a significantly larger decrease in boys than girls. This study 
also demonstrated a dose-response relationship when comparing 
light users (mean decrease 63 g) and heavy users (mean decrease 
189 g). In contrast, babies of mothers using dry snuff in South Af-
rica displayed only a non-significant decrease in birth weight (29.4 
g), whereas those born to smoking mothers displayed a significantly 
lower mean birthweight (165 g) [128]. This discrepancy as com-
pared to the studies from India may be due to differences in type of 
tobacco and possibly lower blood nicotine levels as the amounts of 
snuff was not recorded. Also, as mentioned earlier, this study is 
limited by a complex demographical base with a very high risk for 
confounding factors. 
  In a large study from the Swedish Birth Registry of 789 preg-
nant women using snuff, 11,240 smokers, and 11,495 nonusers, a 
relatively smaller effect on birth weight as compared to smoking 
mothers was also seen. Compared with nonusers, the adjusted mean 
birth weight was reduced in snuff users by 40 g, in light smokers by 
172 g, and in moderate-to heavy smokers by 224 g. As the registry 
contained mothers whose late gestational tobacco use was not 
known (and therefore may represent quitters), the study population 
was also restricted to women whose late pregnancy tobacco expo-
sure was known The adjusted mean birth weight was then reduced 
in snuff users by 93 g, in light smokers by 213 g, and in moderate-
to-heavy smokers by 250 g [25]. This is a large study and the find-
ings clearly suggests that other factors in smoking, e.g. carbon 
monoxide, play a more prominent role than nicotine in fetal growth 
restriction among smokers. However, one major drawback of this 
study is that the amount of snuff was not possible to extract from 
patient records, potentially leading to an underestimation of nico-
tine exposure. 
  In a trial of NRT in pregnancy, babies born to women in the 
nicotine treatment group had significantly higher birth weights than 
those in the placebo group (mean difference 186 g) [138]. This 
again may indicate that other factors than nicotine (e.g. CO or ef-
fects on the placenta) may be responsible for the growth retardation 
seen in children of smoking mothers, but also that the levels of 
nicotine is likely to be of vital importance for possible adverse ef-
fects. It has been thought that the main effect of nicotine on gesta-
tional parameters is caused by a vasoconstriction of uteroplacental 
blood vessels, leading to a reduced blood flow to the placenta and a 
subsequent reduction in the delivery of oxygen and nutrients to 
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demonstrate a correlation between such a uteroplacental insuffi-
ciency and fetal growth retardation, except when blood flow is se-
verely compromised (reviewed in [23]). 
  The neurological consequences of a moderately reduced birth 
weight are not as clear as those of prematurity or of a more pro-
nounced decrease in birthweight [56,130]. A study of IQ in 6-years 
old children has demonstrated a correlation between low birth-
weight and a lower IQ score, also for those with a more moderate 
decrease in birth weight [14]. However, animal studies (further 
discussed below) indicate that birth weight is a poor marker of neu-
rological outcome and that neural consequences may occur at much 
lower doses of nicotine than those required for reducing birth 
weight in the offspring. 
  Another important finding from several studies is that smoke-
less tobacco appears to increase the rate of stillbirth. The associa-
tion was described almost 30 years ago, where tobacco-chewing 
mothers in India were found to have a rate of stillbirth 3 times 
higher than that in nonusers [67]. In western countries, maternal 
cigarette smoking has been causally associated with an increased 
risk for stillbirth; the relative risk ranges from 1.2 to 1.6 [2]. A re-
cent study from India also reports in increased risk for stillbirth 
among users of NST, most of whom used mishri. After adjustment 
for confounding factors, the risk for stillbirth in users was 2.6 with 
a dose–response relationship between the daily frequency of use 
and stillbirth risk. The risk of stillbirth was also greater in earlier 
gestational periods [43]. Use of Smoke-less tobacco use during 
pregnancy thus appears to increase the risk of stillbirth at least as 
much as does maternal cigarette smoking. 
  The effects of maternal smoking during gestation on the risk for 
perinatal morbidity is well demonstrated, showing an increased risk 
in a dose-response fashion. This is illustrated by studies of children 
born to mothers who smoked 20 cigarettes or more, displaying a 
lower 5-minute APGAR scores and umbilical pH level, and more 
than 50% of these newborns required intensive care at the NICU 
[45,131]. Also, the perinatal mortality rate among smokers is 150% 
greater than is seen in non-smokers [66]. No similar studies on 
perinatal morbidity exist to date for NST, with the exception of the 
rate of stillbirth discussed above and neurobehavioural effects dis-
cussed below. 
b. Neurobehavioural Effects 
  The neurobehavioural effects of in utero exposure to tobacco 
via maternal smoking has been reviewed elsewhere [26]. In sum-
mary, the data indicate that in utero exposure to tobacco is associ-
ated with motor, sensory, and cognitive deficits in infants and tod-
dlers, suggesting a toxic effect of tobacco on early neurodevelop-
ment. Similar findings were seen in older infants where maternal 
smoking also was associated with a significant increase in external-
ising (e.g., oppositional, aggressive, overactive) behavioural prob-
lems. The behavioural and cognitive deficits associated with in 
utero exposure to tobacco thus seem to continue into late childhood 
and adolescence and to lead to increased risk for attention-
deficit/hyperactivity disorder (ADHD) and conduct disorder (CD). 
No similar studies exist after in utero exposure to smokeless to-
bacco, leaving the question of what etiological agent(s) of tobacco 
smoke are mediating these effects open. However, animal studies 
(as described further below) indicate an important role for nicotine 
in this pathogenic process.  
  Infants born to smoking mothers are also at increased risk for 
developing nicotine dependence later in life. Signs of abstinence 
and altered behaviour are clearly visible in the perinatal period and 
follow a dose-response relationship [37,70]. During adolescence, a 
greater than 5-fold increased risk of adolescent-onset drug depend-
ence was seen in girls whose mothers smoked 10 or more cigarettes 
almost daily during pregnancy. These findings could not be ex-
plained by maternal substance abuse during pregnancy, parental 
psychiatric diagnosis, family risk factors, prenatal and early devel-
opmental history of offspring, postnatal maternal smoking, or 
smoking in the offspring [134]. A direct specific action by nicotine 
on the developing human brain is possible during a large part of the 
prenatal life, since the nicotinic receptors are already present in the 
brain during the first trimester [52]. 
c. Autonomic Effects and SIDS 
  The association between the risk for Sudden Infant Death Syn-
drome (SIDS) and maternal smoking during pregnancy is well es-
tablished and smoking is the strongest risk factor for SIDS display-
ing a definite dose–response relationship. Maternal smoking of 
more than 20 cigarettes per day increases the relative risk for SIDS 
five-fold [84]. This association was further strengthened following 
the “back to sleep”-campaign, advocating a supine sleeping position 
for all newborns. Whereas this reduced the incidence of SIDS by 
about 50%, it increased the association with smoking, making it the 
sole most important risk factor [24,54]. It has been estimated that 
approximately 30–40% of all cases of SIDS could be avoided if all 
pregnant women stopped smoking in a population with 30% preg-
nant smokers [138]. 
  As the mechanism behind SIDS is not fully understood, nor has 
the mechanism for the increased risk by maternal smoking been 
elucidated. However, concordant with the hypothesis of an altered 
arousability in SIDS victims, such a deficiency has been demon-
strated in children of smoking mothers [55]. Similarly, it has been 
demonstrated that hypoxic arousal was reduced after maternal 
smoking [72]. Measuring autonomic function in human infants is 
quite complicated as many deficiencies are not visible under basal 
conditions. Therefore, indirect evaluation of the autonomic nervous 
system is often employed, using either challenge tests involving 
measurements of heart rate and blood pressure responses after 
stimulation of peripheral chemoreceptors or baroreceptors, or by 
power spectral analysis of heart rate variability (HRV). In children 
of smoking mothers, an increasing number of cigarettes was corre-
lated with deeper the heart rate (HR) declines and smaller HR rises. 
Also, HR response lag time after the ventilatory response to hyper-
oxia, hypoxia and hypercapnia was 2.5 s greater than that in the 
control group for all three stimuli., This difference also increased 
with the number of cigarettes smoked by the mother in a dose-
dependent manner [127].  
  Similarly, effects on the resting spectral power pattern of heart 
rate during different sleep stages was seen in infants of smoking 
mothers, studied at a median postnatal age of 10.5 weeks. A de-
creased HRV was seen at both ends of the spectrum, resembling the 
effects of long-term smoking in adults [32]. 
  It has also been demonstrated that SIDS victims have a deficit 
of 5-HT receptors in areas in the medulla oblongata, containing 
abundant serotonergic projections to the respiratory system that 
regulate defense mechanisms to exogenous stressors such as as-
phyxia. A decreased serotonergic receptor binding was seen in the 
arcuate and caudal raphe nuclei in the majority of the SIDS victims 
examined [64]. This may result in failure of protective responses to 
life-threatening stressors such as asphyxia, hypoxia, or hypercarbia. 
Recent studies by the same group has further described the abnor-
malities in both 5-HT neuron firing, synthesis, release, and clear-
ance. Male SIDS cases also had slightly lower 5-HT (1A) binding 
density in the raphe obscurus as compared with female cases, thus 
suggesting a neurochemical gender difference that may help explain 
the increased vulnerability of boys to SIDS [100]. 
5. EFFECTS OF PERINATAL NICOTINE IN ANIMAL 
MODELS 
a. Effects on Gestation and the Newborn 
  As with humans, studies in monkeys and sheep demonstrate 
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mother and fetus. However, these effects require extremely high 
doses of nicotine and do not support the uteroplacental insuffi-
ciency model [65,86,104]. Using osmotic pumps during gestation, it 
has been demonstrated in a number of studies that whereas chronic 
nicotine exposure during pregnancy reduces maternal weights, it 
usually does not affect fetal growth [92,101,121]. In other studies, 
signs of gestational toxicity in the form of fetal resorption and in-
trauterine growth retardation are described [35,90,113,120]. How-
ever, in these studies a dose of 6 mg/kg*day free base was used, 
that may lead to maternal mean nicotine levels of approximately 80 
ng/ml [73,87] and thus exceed the levels found in the most heavy 
smokers. In a study which compared the effects of nicotine and 
epinephrine it was concluded that both had similar effects on uter-
ine blood flow and reduced maternal weight gain without affecting 
fetal growth (Birnbaum 1994). It therefore appears that fetal birth 
weight is only moderately affected by a dose of 6 mg/kg*day nico-
tine bitartrate, and has no effect at lower doses. 
  Studies of gestational length in animals are scarce, possibly 
because the relatively shorter gestational periods in rodents blunt 
results. However, there are studies that have indicated a increased 
variability in the timing of birth in rat pups prenatally exposed to 
nicotine [105]. It is important to note that lowering the dose of nico-
tine in rats to the point where growth impairment vanishes, and 
where plasma levels match those of moderate smokers, still pro-
duces all the signs of fetal brain damage that are seen at higher 
doses [116]. This has high clinical relevance since intrauterine 
growth retardation is the most commonly used predictor of adverse 
perinatal outcome in offspring of smokers [24]. 
b. Neurobehavioural Effects 
  Although evidence for a deleterious effect of in utero exposure 
to nicotine on behaviour and cognition later in life seems over-
whelming, it is difficult to separate these effects from other con-
founding environmental and genetic factors, e.g. parental character-
istics such as IQ, maternal health, family psychiatric history and 
substance abuse as well as smoking characteristics. For this reason, 
the use of animal models, which permit the control of environ-
mental factors, becomes critical to validate findings in humans. 
However, especially in the case of neurobehavioural effects, the 
generalization of findings of animal studies to human function re-
quires caution, given species differences and methodological limita-
tions. 
  Enhanced locomotor activity is associated with in utero nicotine 
exposure in several species (e.g. rats, mice, and guinea pigs) 
[4,34,80]. Such enhanced locomotor activity has been considered to 
support the association with ADHD [83], but a direct link is diffi-
cult to establish due to the non-specific nature of the changes in 
locomotor activity in animals.  
  Also, cognitive impairments after prenatal exposure to nicotine 
has been demonstrated in animals. Doses as low as 0.5 mg/kg nico-
tine per day injected during pregnancy, caused selective deficits in 
learning an avoidance response in 2-month old male rats [36]. The 
cognitive effects after nicotine exposure in utero also seem to 
stretch into adulthood. Attention and memory deficits in perform-
ance on various maze tasks were seen in adult offspring of nicotine-
treated rats and mice (1.5–6.0 mg/kg nicotine daily) [71,126,141]. 
These impairments in attention, memory, and learning are also con-
sidered consistent with the cognitive deficits found in psychiatric 
disorders such as ADHD. 
  Not all findings are positive, however, and several studies fail 
to report neurobehavioural effects after in utero nicotine exposure 
[13,102]. This may reflect differences in experimental methodol-
ogy, but also that the cognitive effects are of a relatively small 
magnitude. In addition, it emphasises the great difficulty in per-
forming behavioural studies with the high demands put on the ex-
perimental conditions. Understanding the neuropharmacological 
mechanisms of action of nicotine is essential for understanding the 
behavioural consequences of prenatal exposure to nicotine. 
c. Autonomic Effects and SIDS 
  The effects of prenatal nicotine exposure on autonomic function 
has been investigated in several different species (for review, see 
[46]). These indicate that the resistance to severe hypoxia or anoxia 
is impaired by prenatal nicotine exposure, most likely due to a defi-
cient sympathetic activation during hypoxic stress leading to an 
inadequate respiratory adjustment. These results also correspond 
well to results obtained in infants of smoking mothers. Whether 
these effects are primarily due to direct effects on the cardiorespira-
tory control system, or rather reflect the extensive effects on brain 
and synaptic transmission by prenatal nicotine exposure has not 
been clearly established. The profound effects of prenatal nicotine 
exposure on central and peripheral catecholaminergic pathways are 
however likely to be involved. Decreased levels of catecholamine 
synthesizing enzymes in the brain and adrenals [137] and a de-
creased release of catecholamines [118] may be deleterious for an 
organism during e.g. hypoxic stress and is hypothesized to be in-
volved in the pathogenesis of SIDS. It has also been demonstrated 
that the hypoxic defence mechanisms in prenatally nicotine-
exposed lambs was not further compromised by postnatal nicotine 
exposure [48]. This indicates that the detrimental effects on this 
defence mechanism is established prenatally. 
  As with human infants, a delayed arousal during acute hypoxia 
has been found in prenatally nicotine-exposed 5-day-old lambs 
[47]. This effect was seen using a low maternal nicotine free base 
dose (0.5 mg/kg*day) resulting in an average maternal nicotine 
concentration of 7 ng/ml. 
  An appropriate response to asphyxia includes both arousal and 
autoresuscitation reflexes such as gasping, and a functional autore-
suscitory system is vital for survival during severe or prolonged 
hypoxemia. Since defective defence mechanisms are considered to 
be part of the pathogenesis of SIDS, a deficient autoresuscitation 
may also be expected in animals prenatally exposed to nicotine. 
This was examined in newborn rats using a nicotine tartrate dose of 
6 mg/kg*day in the pregnant dam. Whereas there was no effect of 
prenatal nicotine exposure on the duration of gasping in anoxia at 
an age of 5 or 6 days, the ability to repeatedly autoresuscitate after 
periods of was reduced in nicotine-exposed animals [30]. The same 
group also determined the threshold level of maternal nicotine tar-
trate that could impair protective responses, and found that 3 or 6 
mg/kg/day impaired the ability to autoresuscitate from intermittent 
hypoxia-induced primary apnea but a dose of 1.5 mg/kg/day had no 
effect [31]. This may be part of the underlying mechanism resulting 
in increased mortality seen among nicotine-exposed rat and mouse 
pups during severe hypoxia [120,137]. 
  The response to hypoxia also appears to be partially regulated 
by a nAChRs. In newborn transgenic mouse pups lacking 2-
containing nAChRs, deficits usually associated with maternal to-
bacco and nicotine use, i.e. growth restriction, unstable breathing, 
and impaired arousal and catecholamine biosynthesis were demon-
strated [19]. This indicates that the underlying mechanisms of nico-
tine's detrimental side effects on a range of crucial defensive re-
flexes involve loss of function of nAChR subtypes, possibly via
activity-dependent desensitization. 
d. Limitations of Animal Models 
  Although the detrimental effects of prenatal exposure to to-
bacco smoke have been demonstrated in a large number of epide-
miological studies, determining the underlying biological mecha-
nisms for this association has proven difficult. This is partly caused 
by the lack of relevant physiological and pharmacological models 
in which this may be studied, as the human situation contains nu-
merous confounding factors that are sometimes hard to control. To 
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some investigators have performed studies in which the pregnant 
dams were exposed to environmental tobacco smoke. Although this 
experimental set-up resembles the human situation, results may be 
affected by the fact that the animals are likely to be stressed by the 
smoke complicating interpretation [61,124]. It is in this aspect simi-
lar to other previous attempts of providing nicotine during gestation 
such as via subcutaneous injections. Similarly, administration of 
nicotine via water or food has complications as it leads to dehydra-
tion or anorexia of the pregnant mothers. 
  Instead, most animal models to date have employed nicotine as 
a substitute for tobacco smoke, usually as a continuous infusion 
from an osmotic pump [73,87,91,93,123,137]. Although this en-
ables comparison of total levels of nicotine, this mode of admini-
stration does not fully resemble the normal peaks of plasma nico-
tine levels seen in smokers [10,57]. It does, however, eliminate the 
hemodynamic stress on the developing fetus that the previously 
used injections of nicotine caused [62,119,122]. Osmotic pumps 
deliver a constant amount of nicotine, thereby more resembling the 
delivery mode seen in women using nicotine patches or oral snuff 
than smoking. In most studies, the administered doses range from 1 
to 6 mg /kg*day of nicotine bitartrate, calculated for the initial 
weight of the dam. However, it is sometimes unclear in study pro-
tocols if the dose given is indeed nicotine bitartrate or free base 
nicotine, which constitutes 35% of the nicotine bitartrate dose. The 
commonly used dose of approximately 6 mg/kg*day nicotine bitar-
trate, corresponding to 2.1 mg/kg/day free base nicotine, achieves 
maternal mean nicotine blood levels of approximate 35 ng/ml. To 
set this in the human perspective, it has been demonstrated that a 
dose of 1.5 mg/kg per day produces a plasma nicotine concentration 
in rats similar to that of humans who smoke about 20 cigarettes per 
day [87]. Comparison however requires many factors to be taken 
into account, e.g. the increased nicotine metabolism and differences 
in receptor levels between species. The plasma half-life of nicotine 
in the mouse is 5–7 min and in the rat about 54 min. Therefore, 
higher doses may be required to elicit the same effects in the these 
species [106,115,117]. Also, the difference in neural maturity at 
birth across species complicates comparison. For example, cerebral 
maturity at birth in humans approximates that of a 10-day-old rat 
but this difference is not likely to be even across different brain 
areas as these develop at different times. 
6. NEURAL MECHANISMS OF NICOTINIC ACTIONS
  It has long been known that neurotransmitters during develop-
ment have trophic roles in the cellular and architectural develop-
ment of the central nervous system [17]. Therefore, activation of 
neurotransmitter receptors during development may induce effects 
others than those seen in a mature nervous system, e.g. promotion 
of neural cell replication and differentiation, induction (or preven-
tion) of apoptosis, and affect neuronal migration in the brain. Is also 
follows from this that biological compounds that interfere with 
these developmental roles may interfere with the formation of the 
nervous system, a process that occurs well beyond the time of birth. 
As acetylcholine acts as a trophic factor in brain development, nico-
tine from maternal smoking may be expected to interfere with neu-
rotransmitter function and evoke neurodevelopmental abnormalities 
by disrupting the timing or intensity of neurotrophic actions. Such 
disruption may be expected to have long-term consequences [91]. 
  As mentioned above, findings from human smoker do not obli-
gate an underlying cholinergic mechanism, as cigarette smoke con-
tains thousands of bioactive compounds. Therefore, animal models 
will help our understanding on the specific role of nicotine needs in 
this process. 
a. Nicotinic Receptors During Development 
  Our knowledge about the structure and function of nAChRs 
comes primarily from studies in animals (mainly rodents and 
chicks). There are, however, differences between species where not 
all subunits are expressed in mammals and the developmental 
course of nAChRs differs across species. Generalization to humans 
of findings in animals thus needs to be done with caution.  
  The importance of nAChRs and of nicotinic signaling in neural 
development is reflected in the variation in the distribution in the 
brain with the developmental stage and age. Studies in human fe-
tuses have shown that mRNA expression of subunits 3-5, 7 and 
2-4 of the nAChR is present in the prenatal spinal cord, medulla 
oblongata, pons, cerebellum, mesencephalon, subcortical forebrain 
and cortex during first trimester development, even as early as ges-
tational week 4-5 [51]. This suggests an important role for nAChRs 
in modulating dendritic outgrowth, establishment of neuronal con-
nections and synaptogenesis during development. Recent findings 
in rodents also indicate that the nAChRs are functional very early in 
brain development [5]. 
  It is well established that prenatal exposure to nicotine increases 
nAChR density in regions of the fetal and neonatal human [27,53] 
and rat brain (Hagino and Lee, 1985; Sershen et al. 1982; Slotkin, 
1998; Van de Kamp and Collins,1994) and that this effect may last 
beyond the neonatal period [116]. It is unclear whether this reflects 
a compensatory up-regulation that may be expected in a mature 
brain, or rather is a consequence of a disturbed cellular develop-
ment. Such a disruption may either be a direct effect on nAChRs, or 
indirect via e.g. modulation of NE and DA release which act as 
neurotrophic factors [118]. Up-regulation of nAChRs following 
prenatal nicotine exposure also occurs at low doses, insufficient to 
causefetal growth retardation [92]. The long-term effects of nAChR 
up-regulation in the fetal brain are however difficult to elucidate, as 
numeric up-regulation of nAChRs is in fact rather associated with a 
down-regulated function [77,139]. Therefore, nAChR up-regulation 
may cause an initial hypersensitivity followed by subsequent func-
tional down-regulation. This type of paradoxical effect may be part 
of the explanation for the findings in transgenic mice lacking cer-
tain nAChR subtypes that resemble animals prenatally exposed to 
nicotine [18,19,77]. 
  The hypothesis that the detrimental effects on CNS develop-
ment largely depends on activation of nAChRs is supported by 
findings that areas more dense in such receptors display the largest 
degree of cellular damage [116]. However, alterations are seen also 
in areas that are relatively sparse in nAChRs, such as the cerebel-
lum [122]. This may partly reflect that effects are also mediated by 
presynaptical activation of nAChRs and via other transmitter sys-
tems, but also emphasizes the importance of acetylcholine during 
ontogeny. 
b. Developmental Disruption 
  Acetylcholine has vital functions in virtually all phases of brain 
maturation (recently reviewed by [117]), influencing development 
as early as gastrulation [69]. This effect may well be mediated by 
nAChRs, as there are present and functional receptors in the early 
neural tube stage [5]. Later during development, acetylcholine pro-
motes the switch from replication to differentiation [116] and 
modulates synaptogenesis [91]. Direct actions of nicotine on the 
fetal brain have been shown to induce abnormalities in cell prolif-
eration and differentiation, leading to regionally specific abnormali-
ties in cell number and macromolecular content [89,119]. 
  Nicotine has also been demonstrated to in itself produce brain 
cell damage, as indicated by elevated levels of biomarkers of cell 
damage (e.g., ornithine decarboxylase activity) and decreased levels 
of DNA [123]. As a continued decrease in the number of cells was 
seen until postnatal week 2, it was interpreted as a change in the 
program for the cellular development. This is in line with the con-
cept of perinatal or developmental programming, i.e. a lifelong 
alteration in genomic expression and cellular function in response 
to events during vulnerable periods such as perinatal life [6]. Con-
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as a reduced cellular size lasting until postnatal day 40, was seen in 
rats prenatally exposed to nicotine [107]. Findings of increased 
levels of the primary response gene c-fos in brain regions of ani-
mals prenatally exposed to nicotine suggests involvement in the 
regulation of apoptosis [118]. The constitutive activation of genes 
associated with apoptosis also coincides with the period of maximal 
cell loss [116]. Interestingly, the gross dysmorphology in the brain 
caused by nicotine exposure, is partly overcome even when nicotine 
administration continues through parturition, leading to a relatively 
normal brain morphology when examined later on in adolescence or 
adulthood [108]. However, because the normalization of DNA con-
tent occurs during gliogenesis, it is likely that glial cells and not 
neural cells replaced missing cells. This nicotine-induced apoptosis 
in the developing brain thereby contrasts to the proposed neuropro-
tective effect in the mature brain [60,63] emphasizing the impor-
tance in considering the developmental context. The involvement of 
acetylcholine and nicotine in regulating neuronal apoptosis also 
extends the dependence upon trophic responses to acetylcholine 
into the relatively late phases of brain development including in-
fancy and adolescence [8]. This may be especially crucial for the 
central cholinergic pathways that control learning and memory 
[79,88]. 
c. Effects on Other Neurotransmitter Systems 
  In addition to giving rise to structural changes, nicotine also 
altersneurotransmitterrelease,presumably via a presynaptic nAChR 
modulatory effect. Studies of brain slice preparations have indicated 
an enhanced presynaptic release of ACh, dopamine (DA), nora-
drenaline, 5-HT, g-aminobu-tyric acid, and glutamate [35,140]. 
Also post-synaptically, prenatal nicotine exposure alters receptor-
mediated signalling mechanisms, giving rise to a wide variety of 
effects [142]. The general disruption of cellular development 
caused by nicotine is also likely to contribute to altered synaptic 
function. Such synaptic hypoactivity has been demonstrated for 
catecholamines, both in the immediate postnatal period and into 
adolescence [93].  
  Prenatal nicotine also affects several neuromodulator systems, 
i.e. compounds that mainly act as modulators of synaptic transmis-
sion of other classical neurotransmitters. Such neuromodulators are 
e.g. substance P, which is well known to be involved in respiratory 
control, and galanin in central catecholaminergic pathways. Altera-
tions in these systems may lead to a decreased respiratory response 
when subjected to stress situations [136,137]. These effects of nico-
tine may be of particular interest as deficiencies in neuromodulator 
systems, in contrast to similar deficits in classical neurotransmitter 
systems, may not be detected under basal conditions. However, it 
may be of vital importance when the organism is subjected to vari-
ous types of stress and adequate responses are needed for survival. 
  Thus, the effects of nicotine on the developing nervous system 
causes disruption on multiple levels, ranging from cell damage and 
death to specific alterations of neural activity and disturbances in 
intercellular signalling mechanisms. All of these effects are likely 
contributing to the various disturbances seen after prenatal exposure 
to nicotine. 
7. CONCLUSION 
  Several authors have previously pointed out that possible haz-
ards of nicotine use during pregnancy must be placed in its context, 
i.e. that the alternative is smoking tobacco which is extremely 
harmful to both the woman and her child. In light of the limited 
amount of human data, comparison between the two has been diffi-
cult. However, in clinical praxis it has generally been viewed that 
while smokeless tobacco may not be less harmful than smoking, it 
is unlikely to be more hazardous. In this article, results from human 
and animal data are reviewed that indicate that for some parameters 
this may not be correct. Logically, nicotine replacement should be 
safer than smoking, but several animal studies indicate that the total 
dose of nicotine that the fetus is exposed to may be what really 
matters for brain development. Since conventional doses of NRT 
may be less effective in pregnancy, the higher nicotine doses 
needed may exceed the threshold for alterations in brain develop-
ment and cause fetal harm. Similarly, longer acting nicotine re-
placement products leading to higher doses of total nicotine may 
thereby be more likely to contribute to these effects. Evidence from 
animal experiments indeed support this hypothesis, indicating post-
natal behavioral and cognitive deficits in animals exposed in utero 
as well as molecular alterations affecting neurotransmitter function 
and neural development. These deficits last beyond the newborn 
period and at least into adolescence, thus representing a form of 
perinatal programming. 
  Knowledge about the possible adverse effects of prenatal nico-
tine exposure in humans is to date limited because use of smokeless 
tobacco is relatively uncommon in pregnant women, at least in the 
industrialized world. The few studies that exist on the subject are in 
most cases compromised by a lack of prospective recordings of the 
amount and timing of nicotine exposure during pregnancy. Also, 
the lack of objective measures of nicotine exposure (in e.g. urine or 
hair) decreases the validity of the studies. Furthermore, the numer-
ous confounding environmental variables are problematic in inter-
preting results. Prospective studies of the effects of smokeless to-
bacco during pregnancy will provide new insight and increase our 
knowledge concerning the etiology of the well documented effects 
of smoking during pregnancy, as well as the existence of certain 
vulnerability periods. At present, the common conception that NRT 
is a better alternative than smoking during pregnancy may lead to 
an increased use of smokeless tobacco in both industrialized and 
developing countries. As recent findings indicate that functional 
nAChRs are present very early in neuronal development, and that 
activation at this stage leads to apoptosis and mitotic abnormalities, 
a total abstinence from all forms of nicotine should be advised to 
pregnant women for the entirety of gestation. In clinical praxis, this 
also highlights the importance of counseling and support in assist-
ing pregnant women in altering their behavior. 
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